Çocukluk Çağında Mycoplasma pneumoniae’nin Etken Olarak Saptandığı Pnömoni Olgularının Epidemiyolojik, Klinik ve Radyolojik Özelliklerinin Değerlendirilmesi

Demirbaş, Seda Hançerli; Özdemir, Halil; Yılmaz, Songül; Arga, Gül; Konca, Hatice Kübra; Karahan, Zeynep Ceren; Fítöz, Suat; Çıftçı, Ergın

doi:10.5578/mb.20239902

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In certain regions, MP is the most common pathogen responsible for community-acquired pneumonia (CAP) in children, contributing to more than 40% of cases. Approximately 18% of affected children require hospitalization, underscoring its significance as a major global health concern in pediatric healthcare ( Nir-Paz et al, 2017 ; Hançerli Demirbaş et al, 2023 ). The pathogenesis of MPP is intricate, involving direct damage caused by MP adhesion and toxicity, as well as disruptions in the host’s immune function.…”

Section: Introductionmentioning

confidence: 99%

Wuhu decoction combined with azithromycin for treatment of Mycoplasma pneumoniae pneumonia in Asian children: a systematic review and meta analysis of randomized controlled trials

Yang,

Liu,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: This study constitutes a pioneering systematic review and meta analysis delving into the clinical efficacy and safety of the combined therapy involving Wuhu Decoction and azithromycin for treating Mycoplasma pneumoniae pneumonia in pediatric patients.Methods: This study conducted a comprehensive computerized search, covering 6 Chinese databases and 6 English databases, to collect randomized controlled trials related to the combined use of Wuhu Decoction and azithromycin for treating Mycoplasma pneumoniae pneumonia in pediatric patients. The search was extended until August 2023. Two independent researchers were involved in literature screening, data extraction, and bias risk assessment. Meta-analysis was performed using Stata 14.0 and RevMan 5.4 software. Additionally, meta-regression analysis and subgroup analysis were carried out on primary outcomes to identify potential sources of heterogeneity and confounding factors.Results: A total of 22 randomized controlled trials involving 2,026 patients were included in this study. The combined therapy of Wuhu Decoction and azithromycin demonstrated superior efficacy compared to azithromycin alone (RR = 1.17, 95% CI [1.13, 1.21], p < 0.00001; low certainty of evidence). Additionally, patients receiving the combination therapy experienced significantly reduced the disappearance time of fever (MD = −1.42, 95% CI [−1.84, −1.00], p < 0.00001; very low certainty of evidence), disappearance time of cough (MD = −2.08, 95% CI [−2.44, −1.71], p < 0.00001; very low certainty of evidence), disappearance of pulmonary rales (MD = −1.97, 95% CI [−2.31, −1.63], p < 0.00001; very low certainty of evidence), and disappearance time of wheezing (MD = −1.47, 95% CI [−1.72, −1.22], p < 0.00001; very low certainty of evidence). Meta-regression analysis suggested that course of disease, sample size, and age might be sources of heterogeneity. Subgroup and sensitivity analyses reaffirmed the stability of these results. Furthermore, analyses of secondary outcomes such as T lymphocytes, serum inflammatory factors, and the incidence rate of adverse reactions consistently favored the combination therapy of WHD and azithromycin over azithromycin alone, with statistically significant differences.Conclusion: Based on our meta-analysis findings, the combined therapy of Wuhu Decoction and azithromycin for treating pediatric Mycoplasma pneumoniae pneumonia exhibited superior overall efficacy in comparison to azithromycin monotherapy. However, in the included 22 studies, the majority of evaluated factors showed unclear bias risks, and a persistent bias risk was consistently present within one category. Moreover, due to the low quality of evidence, interpreting these results should be approached with caution. Hence, we emphasize the necessity for future high-quality, multicenter, and large-sample clinical randomized controlled trials. These trials are essential to provide more robust data for evidence-based research and to establish higher-quality evidence support.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, identifier CRD42023465606

show abstract

Section: Introductionmentioning

confidence: 99%